Cost-effectiveness analysis of the 2019 cigarette excise tax reform in the Philippines

被引:4
|
作者
Go Cheng, Kent Jason [1 ]
Garcia Estrada, Miguel Antonio [2 ,3 ]
机构
[1] Syracuse Univ, Maxwell Sch Citizenship & Publ Affairs, Social Sci Dept, 100 Coll Pl,Lyman Hall Rm 309, Syracuse, NY 13244 USA
[2] Univ Philippines Diliman, Sch Econ, Quezon City, Philippines
[3] House Representat, Congress Policy & Budget Res Dept, 3-F Main Bldg, Quezon City, Metro Manila, Philippines
关键词
Cigarette; Sin tax reform; Cost-effectiveness analysis; Cost-benefit analysis; Philippines; SYSTEMATIC ANALYSIS; GLOBAL BURDEN; TOBACCO TAXES; 195; COUNTRIES; TERRITORIES; DISEASE; HEALTH; IMPACT; PRICE;
D O I
10.1016/j.ypmed.2021.106431
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
In this past decade alone, the Philippines has made major strides in increasing the price of cigarettes. This study estimated the cost-effectiveness of the most recent cigarette price increase of about 29% brought about by Republic Act (RA) 11346 in 2019. A static or a single cohort model was populated with locally-sourced inputs whenever possible. Public payer and societal perspectives were taken wherein the former only considered direct costs and tax revenue gained earmarked for the health sector while the latter adds indirect costs in the form of productivity losses. A 7% discount rate was applied. Increasing the price of cigarettes by about 29% was found to prevent about 1961 tobacco-related deaths which translate to about 34,571 disability adjusted life years (DALYs) saved. Savings incurred from hospitalizations prevented and additional excise tax revenues for health was about USD 367 Million. But when productivity losses averted due to the lives saved and the higher cost of hospitalizations were accounted for in the societal perspective, the excise tax reform yielded USD 415 Million net gain. It would save the public payer USD 10,612 per DALY averted while society at large stand to save USD 11,955 per DALY averted. Tax increases like RA 11346 yield significant revenue that can be used towards public health programs.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] ANALYSIS OF THE COST-EFFECTIVENESS OF PACS
    HILSENRATH, PE
    SMITH, WL
    BERBAUM, KS
    FRANKEN, EA
    OWEN, DA
    AMERICAN JOURNAL OF ROENTGENOLOGY, 1991, 156 (01) : 177 - 180
  • [32] THE ANATOMY OF COST-EFFECTIVENESS ANALYSIS
    PETERSON, RD
    EVALUATION REVIEW, 1986, 10 (01) : 29 - 44
  • [33] Medicare and cost-effectiveness analysis
    Neumann, PJ
    Rosen, AB
    Weinstein, MC
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (14): : 1516 - 1522
  • [34] DECISION AND COST-EFFECTIVENESS ANALYSIS
    MARLEY, DS
    JOURNAL OF FAMILY PRACTICE, 1990, 30 (02): : 233 - &
  • [35] COST-EFFECTIVENESS ANALYSIS - A REVIEW
    RUTIGLIANO, MJ
    NEUROSURGERY, 1995, 37 (03) : 436 - 443
  • [36] THE ROAD TO COST-EFFECTIVENESS ANALYSIS
    KLARMAN, HE
    MILBANK MEMORIAL FUND QUARTERLY-HEALTH AND SOCIETY, 1982, 60 (04): : 585 - 603
  • [37] Overview of Cost-effectiveness Analysis
    Sanders, Gillian D.
    Maciejewski, Matthew L.
    Basu, Anirban
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (14): : 1400 - 1401
  • [38] Cost-effectiveness analysis of paclitaxel
    Eandi, Mario
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2006, 7 (02) : 97 - 117
  • [39] Is cost-effectiveness analysis unfair?
    Russell, LB
    MEDICAL DECISION MAKING, 2004, 24 (02) : 232 - 234
  • [40] Cost-effectiveness analysis - Reply
    Hueston, WJ
    JOURNAL OF FAMILY PRACTICE, 1997, 44 (06): : 524 - 525